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T. Zeller 1 , C. Schurmann 2 , K. Schramm 3 , C. Muller 1 , S. Kwon 4 , P. Wild 5 , L. Iacoviello 6 , M. Karakas 1 , R.B. Schnabel 1 , J.I. Rotter 4 , S.B. Felix 2 , X. Guo 4 , C. Herder 7 , S. Blankenberg 1 , G. Homuth 2 . 1 University Heart Center Hamburg, Clinic for General & Interventional Cardiology, Hamburg, Germany; 2 University Medicine of Greifswald, Greifswald, Germany; Munich, Germany; 4 University of California Los Angeles, Los Angeles, United States of America; 5 University Medical Center, Department of Medicine 2, Mainz, Germany; 6 Neuromed Institute IRCCS, Pozzilli, Italy; 7 Heinrich Heine University, Dusseldorf, Germany Background: Hypertension is a major cardiovascular risk factor. The pathophysiological nature of increased blood pressure (BP) is not yet completely understood. Transcriptome profiling offers novel possibilities to uncover genetics effects on blood pressure. Methods: Based on four populations including 4,533 individuals a meta-analysis of transcriptome-wide profiles was performed to identify transcripts associated with BP traits. A direct link between long-term changes in BP and gene expression over time, and treatment with BP-lowering therapy was assessed. The predictive value of protein levels encoded by candidate genes for subsequent BP-related cardiovascular disease was investigated. Result: Eight genes (CRIP1, MYADM, TIPARP, TSC22D3, CEBPA, F12, LMNA, TPPP3) were identified jointly explaining up to 11% (95% confidence interval (CI), 7.6, 14.5) of BP variability. Changes in CRIP1, MYADM, TIPARP, LMNA and TPPP3 expression associated with long-term changes in BP over 5 years and BP-lowering therapy associated with the expression of seven transcripts. In both longitudinal analyses CRIP1 (Cystein-Rich (intestinal) Protein 1) levels showed the strongest association to BP changes (5y-changes: delta mRNA SBP: 2.93±0.45, p=2.15×10-10; delta mRNA DBP: 5.19±0.77, p=8.46×10-11; delta mRNA PP: 2.2±0.62, p=5.0×10-4; BP-lowering medication: % mRNA change: -34.14% ± 3.55; p=5.6×10-14). Gene expression levels -in particular CRIP1 levels -were additionally correlated to measures of cardiac hypertrophy. Assessment of circulating CRIP1 protein levels as biomarker showed a strong association with incident stroke (HR 1.06; 95% CI 1.03, 1.09, p=4.97×10-5). Conclusion: Our comprehensive analysis of global gene expression highlights 8 novel transcripts significantly associated with BP providing a direct link between gene expression and BP. Translational approaches further established evidence for the potential use of CRIP1 as emerging cardiovascular biomarker. Our data provide novel insights of the pathogenesis of increased BP and hypertension and -in the long term -for therapeutic development/intervention with respect to BP control. Background: The purpose of this study was to analyze the results of array comparative genomic hybridization (a-CGH) performed in neonates with congenital heart disease (CHD) in a tertiary hospital and investigate the advantages and disadvantages of verifying genetic abnormality using a-CGH immediately after diagnosis of CHD. Methods: Among neonates under the age of 28 days who underwent echocardiography from January 1, 2014 to April 30, 2016, neonates whose chromosomal and genomic abnormalities were tested using a-CGH in cases of an abnormal finding on echocardiography were enrolled. Their medical records were reviewed retrospectively. Results: Two hundred and fourty-seven neonates underwent echocardiography during the research period. Of the patients diagnosed with CHD, 81 underwent a-CGH and 11 patients (11/81, 13.5%) had abnormal findings on a-CGH. 22q11.2 deletion syndrome was the most common test results with each being found in four patients. On the first a-CGH, four patients were negative (4/81, 5%). Three of them were finally diagnosed with Williams syndrome using fluorescent in-situ hybridization (FISH), one patient was diagnosed with Noonan syndrome through exome sequencing. All of them exhibited diffuse pulmonary artery branch hypoplasia, as well as increased velocity of blood flow, on repeated echocardiography. Five patients started rehabilitation therapy at mean 6 months old age in outpatient clinics and seizures were suspected in two patients due to their abnormal movements or seizing. Two patients (22q11.2 deletion syndrome and Patau syndrome)' parents refused treatment due to the anticipated prognosis. Conclusions: Screening tests for genetic abnormalities using a-CGH in neonates with CHD has the advantage of early diagnosis of genetic abnormality during the neonatal period in which there is no obvious symptom of genetic abnormality. Furthermore, early rehabilitation therapy was feasible as the neurological prognosis could be predicted. However, there are disadvantages that some genetic abnormalities cannot be identified on a-CGH. Introduction: The chromosomal locus 4q32.1 harbouring the GUCY1A3 gene, which encodes the alpha1-subunit of the soluble guanylyl cyclase (sGC), has been genome-wide significantly associated with coronary artery disease (CAD) and myocardial infarction. The link between common, non-coding variants at the locus with CAD risk remains to be identified. Methods and results: Migration of vascular smooth muscle cells (VSMC) homozygous for the risk and the non-risk allele, respectively, was assessed using scratch wound assays. Homozygous non-risk allele VSMC displayed significantly reduced migration compared to homozygous risk allele VSMC secondary to stimulation of the sGC. Response to sGC stimulation was also investigated in platelets of carriers of the different genotypes. Baseline ADP-induced platelet aggregation did not differ between the genotypes. After stimulation of the sGC, inhibition of platelet aggregation was significantly stronger in platelets homozygously carrying the non-risk allele compared to those only only carrying the risk allele. The effect was further enhanced after inhibition of cGMP degradation using the phosphodiesterase 5 inhibitor sildenafil. GUCY1A3 expression was significantly lower in whole blood, VSMC and platelets of homozygous risk allele carriers. In silico analyses located a DNase I hypersensitivity site to the lead single nucleotide polymorphism rs7692387 and predicted binding of a transcription factor rather to the Downloaded from https://academic.oup.com/eurheartj/article-abstract/38/suppl_1/ehx504.P4468/4090511 by guest on 31 December 2018
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